| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.8M | -5.9% | +56.5% |
| SG&A Expense | $1.6M | +56.8% | +59.6% |
| Operating Income | -$3.4M | -16.2% | -58.0% |
| Net Income | -$3.4M | -16.1% | -58.2% |
| EPS (Basic) | -$1.28 | +2.3% | -91.0% |
| EPS (Diluted) | -$1.28 | +2.3% | -91.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.1M | -20.8% | -14.6% |
| Current Assets | $4.7M | -15.8% | -11.8% |
| Total Assets | $4.8M | -15.7% | -12.4% |
| Current Liabilities | $2.8M | +19.5% | +60.9% |
| Total Liabilities | $2.8M | +18.5% | +55.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.2M | — | — |
| Financing Cash Flow | $6.2M | — | — |
| $2.0M |
| -40.0% |
| -45.5% |